CJC 1295 w/o DAC (5mg)
Product Overview
CJC-1295 Without DAC (Modified GRF 1-29) is a tetrasubstituted synthetic analogue of endogenous human growth hormone-releasing hormone (GHRH), a 44-amino acid hypothalamic neuropeptide that physiologically governs pituitary somatotroph activation and downstream GH-IGF-1 axis regulation. The reagent’s 29-amino acid truncated sequence corresponds to the bioactive N-terminal fragment of GHRH, retaining full GHRH receptor (GHRHR) binding competence. Theratechnologies Inc. originally developed this scaffold in the early 2000s as a stabilised GHRH analogue platform. The no-DAC variant — without the maleimidopropionic acid (MPA) albumin-binding conjugate — produces pulsatile receptor stimulation that more closely recapitulates endogenous hypothalamic GHRH secretion rhythms in preclinical models.
The absence of the Drug Affinity Complex is a defining research feature, not a limitation. In experimental designs where the primary endpoint is investigation of discrete GH pulse architecture, somatostatin interplay, or circadian GH axis rhythmicity, the short half-life of the no-DAC form is precisely what ensures physiologically relevant pulse-to-pulse resolution in the data. This makes CJC-1295 Without DAC the preferred GHRH analogue reagent for studies pairing it with growth hormone secretagogue receptor (GHSR) agonist compounds, where synergistic dual-pathway somatotroph activation is the target endpoint.
CJC-1295 Without DAC is a 29-amino acid synthetic peptide with molecular formula C152H252N44O42 and molecular weight 3,367.9 g/mol (PubChem CID 91976842). It is the tetrasubstituted N-terminal fragment of human GHRH, modified at four residue positions to resist enzymatic degradation: D-Ala replaces L-Ala at position 2 to block DPP-IV cleavage; Gln or Aib replaces Gly at position 8 to prevent asparagine rearrangement; modified Ala at position 15 enhances receptor binding bioactivity; and Leu replaces Met at position 27 to prevent methionine oxidation.
These modifications extend the functional half-life from native GHRH’s approximately 7 minutes to approximately 30 minutes while preserving full GHRH receptor binding selectivity. The large topological polar surface area (~1,450 Å2) and high molecular weight are consistent with a flexible, biologically active peptide scaffold. PubChem computed properties confirm 52 hydrogen-bond donors, 48 acceptors, and 118 rotatable bonds.
DISCLAIMER:
- Products sold on our website are meant for scientific research purposes only, designed for in vitro testing and lab experimentation exclusively. These products are not intended to be used as foods, drugs or cosmetics, any sort of bodily introduction of the products into humans or animals is strictly prohibited.
- All the products you see on the website are being sold as a freeze dried powder, in a sealed sterile vial; and should be reconstituted.
The product’s label clearly states the amount of product a vial contains; some products are offered in different variations. - The products we are selling come in a sealed vial but require additional lab equipment for proper testing.
- Though we make sure packaging, label, seals and writing does not differ from the product photos you see on our website, there is a chance for a minimal deviation.
Frequently bought together
-
BPC-157 (10mg)
Original price was: $80.00.$65.00Current price is: $65.00. -
IGF-LR3 (1mg)
Original price was: $90.00.$70.00Current price is: $70.00. -
KLOW (80mg)
Original price was: $150.00.$125.00Current price is: $125.00. -
NAD+
Original price was: $93.00.$75.00Current price is: $75.00. -
TB-500 (5mg)
Original price was: $75.00.$55.00Current price is: $55.00.





